NCT01660893终止3 期
A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 26
- 试验地点
- 3
- 主要终点
- Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).
研究概览
简要总结
The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and Placebo for inducing pulpal anesthesia of the maxillary teeth in adults.
详细描述
The study will employ a multi-center, randomized, double-blind, placebo-controlled, parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary right second premolar to maxillary left second premolar) sufficient to allow completion of the Study Dental Procedure.
A total of 140 subjects, randomized 2:2:1 (Kovacaine Mist:Tetracaine alone:Placebo) will be enrolled to achieve 125 completed subjects; a total of 50 Kovacaine Mist subjects, 50 tetracaine alone subjects and 25 placebo subjects. Recruitment will be from diverse dental patient populations. At the two study sites, a balanced enrollment of 70 subjects each is planned to allow for a potential 10% drop-out rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 18 years of age or older.
- •Need for an operative restorative dental procedure requiring local anesthesia for a single vital maxillary tooth (other than a maxillary first, second, or third molar) with no evidence of pulpal pathology.
- •Normal lip, nose, eyelid, and cheek sensation.
- •Able to understand and sign the study informed consent document, communicate with the investigators, and understand and comply with the requirements of the protocol.
- •Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.
- •Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.
- •Seated systolic blood pressure (SBP) between 95 and 140 mm Hg, inclusive and seated diastolic blood pressure (DBP) between 60 and 90 mm Hg, inclusive.
排除标准
- •Inadequately controlled hypertension (blood pressure greater than 140/90 mm Hg).
- •Inadequately controlled active thyroid disease of any type.
- •Frequent nose bleeds (≥ 5 per month).
- •Having received dental care requiring a local anesthetic within the last 24 hours.
- •History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).
- •History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or sulfite preservatives.
- •Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.
- •Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females of child-bearing potential will be required to take a urine pregnancy test on the day of, but prior to, study drug administration to rule out pregnancy.)
- •Having received any investigational drug and/or participation in any clinical trial within 30 days prior to study participation.
- •Having used oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other nasal or oral decongestant on the day of the study procedure.
- •History of congenital or idiopathic methemoglobinemia
研究组 & 干预措施
Kovacaine Mist, 3 sprays unilateral
Experimental
Tetracaine HCl 3% and oxymetazoline HCl 0.05%
干预措施: Tetracaine HCl 3% and oxymetazoline HCl 0.05% (Drug)
Tetracaine Only, 3 sprays unilateral
Experimental
Tetracaine HCl 3%
干预措施: Tetracaine HCl 3% (Drug)
Placebo, 3 sprays unilateral
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).
时间窗: at 15 minutes with a 3 minute window
次要结局
- Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg(at any time within 120 minutes following drug administration)
- Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg(at any time within 120 minutes following drug administration)
- The Profile Over Time of Heart Rate(from baseline to 120 minutes following drug administration)
- The Profile Over Time of Diastolic Blood Pressure(from baseline to 120 minutes following drug administration)
- Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg(at any time within 120 minutes following drug administration)
- Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg(at any time within 120 minutes following drug administration)
- Intraoral Soft-tissue Anesthesia (Yes/no)(at 15 minutes with a 3 minute window)
- Number of Participants With Heart Rate Higher Than 125 Bpm(at any time within 120 minutes following drug administration)
- Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure(from baseline to 120 minutes following drug administration)
- Number of Participants With Heart Rate Lower Than 50 Bpm(at any time within 120 minutes following drug administration)
- The Profile Over Time of Systolic Blood Pressure(from baseline to 120 minutes following drug administration)
- Alcohol Sniff Test(administered at approximately 24 hours after drug administration)
- Absolute Maximum Change From Baseline in Heart Rate(from baseline to 120 minutes following drug administration)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)HypertensionNCT00274716Merck Sharp & Dohme LLC249
终止
3 期
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.Thyroid Eye DiseaseNCT06307626argenx105
终止
3 期
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseThyroid Eye DiseaseNCT06307613argenx102
终止
3 期
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANon-Small Cell Lung CancerNCT03447769Novartis Pharmaceuticals1,382
已完成
2 期
A Study of Acute Myocardial Infarction Using FDY-5301Acute Myocardial InfarctionSTEMINCT03470441Faraday Pharmaceuticals, Inc.120